AK Psychology Group | Evidence-Based Perspectives on Psychedelic-Assisted Therapy
There is a moment that can arrive unexpectedly during a psychedelic journey. You might find yourself face-to-face with a memory you have spent years avoiding, or suddenly aware of a pattern you have been blind to. The medicine shows you something true about yourself, and with that truth comes a flood of difficult emotions: shame, guilt, grief, anger, or despair so intense it feels overwhelming.
If you have experienced something like this, you are not alone. What many people do not realize is that these moments of profound discomfort may actually be where healing begins.
What Science Reveals About Difficult Emotions
In a large naturalistic study published in 2025, researchers explored the experiences of over 300 individuals who had taken psilocybin outside of clinical settings. More than two-thirds of participants reported experiencing shame or guilt during their journey, emotions that were intense, complex, and persistent throughout significant portions of their experience (Davis et al., 2025).
What emerged from this data is a fundamental reframe: these emotions were not detours from healing or signs of therapeutic failure. Participants who experienced and successfully processed these emotions showed greater improvements in well-being weeks and months later than those who did not encounter such challenges. The presence of difficult emotions was not the determining factor in long-term outcomes. It was the participant’s ability to work through them constructively that predicted therapeutic benefit.
What we often label as a bad trip may actually be the moment therapy begins, not because something is wrong, but because something real and therapeutically relevant is ready to be addressed.
Understanding Through Depth Psychology
Psychoanalyst Daniel Shaw’s work on self-alienation provides a useful bridge. Shaw explains that emotions like shame, particularly when rooted in early relational trauma, create what he terms self-alienation: an internal split where one part of the psyche observes and judges another part as fundamentally flawed. This division operates largely outside conscious awareness but profoundly shapes emotional regulation and relational patterns.
The research suggests that psychedelics may temporarily dissolve these internal barriers, creating opportunities for reconnection with parts of ourselves long exiled. During this state of enhanced neuroplasticity, individuals can experience glimpses of self-compassion and psychological wholeness that may have been inaccessible for years. However, Shaw’s clinical observations align precisely with the research findings: without proper therapeutic support, old patterns of self-judgment often return more forcefully than before.
Evidence-Based Integration in Practice
Translating these findings into clinical practice requires a structured approach. In the immediate post-session period (days 1 to 7), clinical focus centers on emotional containment and nervous system regulation rather than cognitive processing. In the active integration phase (weeks 2 to 4), structured therapeutic exploration becomes possible, including meaning-making, emotional processing, and translating insights into behavioral changes. The sustained integration phase (beyond week 4) emphasizes embedding new patterns into daily life and relationships.
